Extension of in vivo half-life of biologically active molecules by XTEN protein polymers.

XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia coli and purified by conventional protein chromatography as monodisperse polypeptides of exact length and sequence. Unstructured XTEN polypeptides have hydrodynamic volumes significantly larger than typical globular proteins of similar mass, thus imparting a bulking effect to the therapeutic payloads attached to them. Since their invention, XTEN polypeptides have been utilized to extend the half-lives of a variety of peptide- and protein-based therapeutics. Multiple clinical and preclinical studies and related drug discovery and development efforts are in progress. This review details the most current understanding of physicochemical properties and biological behavior of XTEN and XTENylated molecules. Additionally, the development path and status of several advanced drug discovery and development efforts are highlighted.

[1]  F. Perez-Ruiz,et al.  PEG-uricase in the management of treatment-resistant gout and hyperuricemia. , 2008, Advanced drug delivery reviews.

[2]  A. Tsourkas,et al.  Quantitative Comparison of Tumor Delivery for Multiple Targeted Nanoparticles Simultaneously by Multiplex ICP-MS , 2014, Scientific Reports.

[3]  Ian Kimber,et al.  Immunogenicity of therapeutic proteins: Influence of aggregation , 2013, Journal of immunotoxicology.

[4]  T. Bailey,et al.  A Long-Acting Human Growth Hormone With Delayed Clearance (VRS-317): Results of a Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Growth Hormone–Deficient Adults , 2013, The Journal of clinical endocrinology and metabolism.

[5]  Inger Sandlie,et al.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics , 2015, Front. Immunol..

[6]  R. Offord,et al.  Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. , 1996, Bioconjugate chemistry.

[7]  W. Stemmer,et al.  GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model , 2012, PloS one.

[8]  M. Scholle,et al.  Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose , 2010, PloS one.

[9]  B. Larijani,et al.  The importance of hypoglycemia in diabetic patients , 2012, Journal of Diabetes & Metabolic Disorders.

[10]  D. DiMichele Inhibitors in Hemophilia: A Primer , 2008 .

[11]  T. Parry,et al.  Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. , 2002, European journal of pharmacology.

[12]  Andrew Tsourkas,et al.  ICP-MS analysis of lanthanide-doped nanoparticles as a non-radiative, multiplex approach to quantify biodistribution and blood clearance. , 2012, Biomaterials.

[13]  K. Geoghegan,et al.  Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. , 1992, Bioconjugate chemistry.

[14]  D. Dunger,et al.  Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. , 2003, Diabetes care.

[15]  S. Harding,et al.  Hydrodynamic characterisation of chemically degraded hyaluronic acid , 2003 .

[16]  F. Szoka,et al.  The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. , 2015, Advanced drug delivery reviews.

[17]  Stephan M. Koza,et al.  Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates , 2012, Journal of liquid chromatography & related technologies.

[18]  R. Kontermann,et al.  Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives , 2012 .

[19]  I. Kaltashov,et al.  Structural characterization of protein–polymer conjugates. I. Assessing heterogeneity of a small PEGylated protein and mapping conjugation sites using ion exchange chromatography and top-down tandem mass spectrometry , 2012 .

[20]  V. Lubchenko,et al.  The use of dynamic light scattering and brownian microscopy to characterize protein aggregation. , 2011, The Review of scientific instruments.

[21]  J. Holst,et al.  In vivo and in vitro degradation of glucagon-like peptide-2 in humans. , 2000, The Journal of clinical endocrinology and metabolism.

[22]  Lihua Huang,et al.  Elucidation of PEGylation site with a combined approach of in-source fragmentation and CID MS/MS , 2010, Journal of the American Society for Mass Spectrometry.

[23]  K. Campbell,et al.  Staining of the Ca2+-binding proteins, calsequestrin, calmodulin, troponin C, and S-100, with the cationic carbocyanine dye "Stains-all". , 1983, The Journal of biological chemistry.

[24]  A. Klibanov,et al.  Hydrophobic salts markedly diminish viscosity of concentrated protein solutions , 2011, Biotechnology and bioengineering.

[25]  J. Aronson Safety , 2009, BMJ : British Medical Journal.

[26]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  Jan Jezek,et al.  Viscosity of concentrated therapeutic protein compositions. , 2011, Advanced drug delivery reviews.

[28]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[29]  R. Rosenfeld,et al.  Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[30]  B. E. Kimmel,et al.  Optimized clinical performance of growth hormone with an expanded genetic code , 2011, Proceedings of the National Academy of Sciences.

[31]  C. Gu,et al.  Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. , 2013, Protein engineering, design & selection : PEDS.

[32]  M. Mouksassi,et al.  Population Pharmacokinetics of Teduglutide Following Repeated Subcutanenous Administrations in Healthy Participants and in Patients With Short Bowel Syndrome and Crohn's Disease , 2010, Journal of clinical pharmacology.

[33]  Yuanguo Cheng,et al.  Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. , 2008, International journal of pharmaceutics.

[34]  F. O'Brien,et al.  Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. , 2005, Pediatric endocrinology reviews : PER.

[35]  E. Åkerblom,et al.  Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. , 1984, International archives of allergy and applied immunology.

[36]  J. Stockman Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .

[37]  G. Pasut Polymers for Protein Conjugation , 2014 .

[38]  Chee-Youb Won,et al.  PEG-modified biopharmaceuticals. , 2009, Expert opinion on drug delivery.

[39]  O. Tanner Intensive versus Conventional Glucose Control in Critically Ill Patients , 2009 .

[40]  D. Dunger,et al.  Monitoring of concordance in growth hormone therapy , 2007, Archives of Disease in Childhood.

[41]  R. Kaufman,et al.  A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Costel C. Darie,et al.  Trends in Characterization of PEGylated Proteins by Mass Spectrometry , 2014 .

[43]  B. Hamm,et al.  XTEN-Annexin A5: XTEN Allows Complete Expression of Long-Circulating Protein-Based Imaging Probes as Recombinant Alternative to PEGylation , 2014, The Journal of Nuclear Medicine.

[44]  B. Trathnigg Size Exclusion Chromatography of Polymers , 2003 .

[45]  P. Donnan,et al.  Frequency and predictors of hypoglycaemia in Type 1 and insulin‐treated Type 2 diabetes: a population‐based study , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[46]  M. A. Hartman,et al.  Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility , 2014, Bioconjugate chemistry.

[47]  B. Nielsen,et al.  Recombinant Factor IX , 1997, Thrombosis and Haemostasis.

[48]  Dimichele Inhibitors in haemophilia: a primer , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[49]  H. Heyneker,et al.  High-level secretion of human growth hormone by Escherichia coli. , 1987, Gene.

[50]  J. Gebler,et al.  Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. , 2009, Analytical chemistry.

[51]  Francesco M Veronese,et al.  State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[52]  T. Nichols,et al.  Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. , 2011, Blood.

[53]  J. Powell,et al.  Longer‐acting clotting factor concentrates for hemophilia , 2015, Journal of thrombosis and haemostasis : JTH.

[54]  W. Stemmer,et al.  A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life , 2012, Journal of pharmaceutical sciences.

[55]  M. Mouksassi,et al.  Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon‐Like Peptide‐2 (GLP‐2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects , 2008, Journal of clinical pharmacology.

[56]  Mohammed Shameem,et al.  Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications , 2014, mAbs.

[57]  Pascal Richette,et al.  Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents , 2012, Expert opinion on drug delivery.

[58]  Ray Yin,et al.  A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. , 2011, Journal of pharmacological and toxicological methods.

[59]  A. Gunn,et al.  Non-Compliance with Growth Hormone Treatment in Children Is Common and Impairs Linear Growth , 2011, PloS one.

[60]  D. Rudmann,et al.  High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins , 2013, Toxicologic pathology.

[61]  N. Shah,et al.  Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia , 2012, Diabetes Care.

[62]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[63]  P. Lenting,et al.  The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.

[64]  荒井保明 Pharmacokinetics , 1993 .

[65]  Lihua Huang,et al.  Characterization of poly(ethylene glycol) and PEGylated products by LC/MS with postcolumn addition of amines. , 2009, Analytical chemistry.

[66]  H. Goldberg,et al.  The staining of acidic proteins on polyacrylamide gels: enhanced sensitivity and stability of "Stains-all" staining in combination with silver nitrate. , 1997, Analytical biochemistry.

[67]  L. Vincent,et al.  Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent Anti-Human Immunodeficiency Virus Type 1 Activity , 2009, Antimicrobial Agents and Chemotherapy.

[68]  A. Dornhorst,et al.  PREDICTIVE™– a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort , 2007, Diabetes, obesity & metabolism.

[69]  P. Schnier,et al.  Gas-phase proton-transfer chemistry coupled with TOF mass spectrometry and ion mobility-MS for the facile analysis of poly(ethylene glycols) and PEGylated polypeptide conjugates. , 2008, Analytical chemistry.

[70]  Herbert J Meiselman,et al.  Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.

[71]  Willem P C Stemmer,et al.  A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner , 2009, Nature Biotechnology.

[72]  Huub Schellekens,et al.  The Immunogenicity of Polyethylene Glycol: Facts and Fiction , 2013, Pharmaceutical Research.

[73]  S. Schmidt Fusion Proteins for Half‐Life Extension , 2013 .

[74]  Ambady Ramachandran,et al.  Hypoglycemia: The neglected complication , 2013, Indian journal of endocrinology and metabolism.

[75]  David J Brayden,et al.  Advances in PEGylation of important biotech molecules: delivery aspects , 2008, Expert opinion on drug delivery.

[76]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[77]  Kang-Choon Lee,et al.  Emerging PEGylated drugs , 2009, Expert opinion on emerging drugs.

[78]  G. Shopp,et al.  Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[79]  K. Geoghegan,et al.  Site‐Directed Conjugation of Nonpeptide Groups to Peptides and Proteins via Periodate Oxidation of a 2‐Amino Alcohol. Application to Modification at N‐Terminal Serine. , 1992 .